The effect of valproate sodium on treatment of patients with mania
Phase 2
- Conditions
- bipolarity- mania episode.Manic episode
- Registration Number
- IRCT201108087260N1
- Lead Sponsor
- Vice chancellor of research and technology & Research institute for behavioral disorder and substanc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Patients who are in acute mania episode. Exclusion criteria: patients with other psychiatric disorders.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma level. Timepoint: one, three and seven days after injection. Method of measurement: measure of plasma level.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie valproate sodium's efficacy in acute mania compared to lithium?
How does intravenous valproate loading dose compare to oral administration in bipolar disorder mania management?
Which biomarkers predict response to valproate sodium in patients with mixed manic-depressive episodes?
What are the adverse event profiles of valproate sodium IV vs oral routes in acute mania trials?
How does valproate sodium's mechanism of action relate to AMPK activation in bipolar disorder treatment?